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Abstract 
During the last ten years, the conference on “Steroids and Nervous System” 
held in Torino (Italy) was an important international point of discussion for scientists 
involved in this exciting and expanding research field. The present review aimed to 
recapitulate the main topics that were presented through the various editions of the 
meeting. Two broad areas were explored: the impact of gonadal hormones on brain 
circuits and behaviour, and the mechanism of action of neuroactive steroids. 
Relationships among steroids, brain and behaviour, the sexual differentiation of the 
brain and the impact of gonadal hormones, the interactions of exogenous steroidal 
molecules (endocrine disrupters) with neural circuits and behaviour, and how gonadal 
steroids modulate the behaviour of GnRH neurones were the topics of several lectures 
and symposia during this series of meetings. At the same time, many contributions 
were dedicated to the biosynthetic pathways, the physiopathological relevance of 
neurosteroids, and the demonstration of the cellular localization of different enzymes 
involved in neurosteroidogenesis, the mechanisms by which steroids may exert some 
of their effects, both classical and non-classical action of different steroids, the role of 
neuroactive steroids on neurodegeneration, neuroprotection and the response of the 
neural tissue to injury. In these 10 years, this field has significantly advanced and 
neuroactive steroids have emerged as new potential therapeutic tools to counteract 
neurodegenerative events. 
 
Keywords: neurosteroids, brain, peripheral nerve, sex difference, neuroprotection, 
GnRH, kisspeptin, behaviour 
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The conference on “Steroids and the Nervous System” emerged as a “spin-off” from a 
conference specifically dedicated to the neuroendocrine controls of behaviour. The 
International Conference on Hormones, Brain and Behaviour" (ICHBB) met several 
times in various locations in Europe during the eighties and nineties (Bielfeld, 
Germany, 1982; Liege, BE, 1984 and 1989; Tours, FR, 1993; Torino, IT, 1996 and 
finally Madrid, SP, 2000). After ICHBB was merged with the activities of the Society 
for Behavioral Neuroendocrinology (SBN) that had been created in 1997, Gian Carlo 
Panzica (University of Torino) and Roberto C. Melcangi (University of Milan) 
decided that it would be important to keep a conference regularly meeting in Europe 
and dealing with steroid action in the brain. A cycle of conferences using essentially 
the same format as ICHBB was therefore initiated that has now met every two years 
for the past 10 years (2001, 2003, 2005, 2007, 2009 and 2011, fig.1) (see 
http://www.dafml.unito.it/anatomy/panzica/neurosteroids/ABSTRACTBOOKS.htm).  
The scope of the conference has been expanded from the behavioural effects of 
steroids in the brain to cover all forms of steroid actions, the controls of steroid 
synthesis in the brain and in the peripheral nervous system, as well as the emerging 
translational models.  
 
Steroids and behaviour at the Torino meeting 
Glancing through the programs of these 6 conferences summarizing 10 years of 
research on steroids, one can identify a large number of symposia that were 
essentially or even exclusively dedicated to “Steroids, Brain and Behaviour”. The 
topics that were covered in these symposia concern many aspects of the active 
research that took place in this field during the last decade.  To list just a few, we had 
over the years the chance of attending symposia dedicated to behavioural effects of 
steroids as well as to the action of environmental oestrogens on behaviourally relevant 
neural circuits (2003) (1), on brain sexual differentiation (2005), on the importance of 
co-regulatory factors for steroid receptor action in the brain (2009) and on 
experimental murine models  (2011).  
Several round tables were also organised within the meeting during which we 
discussed the action of endocrine disrupter action on behaviour and neuroendocrine 
system (2005, 2011), and that of steroid hormones on sexually dimorphic brain 
circuits (2007). It must be mentioned that, as impressive as they are, all these 
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symposia only provide a partial view of the time and talks that were devoted to 
behaviour during the meeting on Steroids and Nervous System. There were indeed 
many individual presentations on behaviour embedded in other symposia and these 
are far too numerous to be cited here. Starting from 2003, each meeting had 
additionally a few (usually 3) key-note speakers and many of the key-note lectures 
concerned, at least in part, the mechanisms of behaviour. During the 2003 meeting the 
attention was focused on the oestradiol modulation of astrocytes and the 
establishment of sex differences in the brain (2) and on the role of sex chromosomes 
in sexual differentiation of the brain (3). In the 2005 meeting, the speakers presented 
data on the rapid changes in the production and behavioural action of oestrogens (4) 
and on genetic models for the study of gonadal steroid dependent behaviours (5). In 
2007 the attention was on the stress system in the human brain in depression and 
neurodegeneration (6). In 2009 meeting one of the key-note lectures was on the 
intracellular signal transduction cascades mediating behavioural effects of ovarian 
steroids (7). Finally, in 2011 we had lectures on comparative and functional 
implications of neurosteroidogenesis (8) and on oestrogen-induced plasticity and 
cognitive function (9). And that is without counting the large number of posters that 
were presented on themes related to the main talks and symposia and that were very 
often using behaviour as their dependent (or sometimes independent) variable. 
Finally, in association with the “Torino meeting“, as it has often been 
colloquially named, a satellite one-day symposium entirely dedicated to the endocrine 
control of behaviour was organised in 2009. It was named 7th ICHBB to celebrate the 
synchronised 60th birthday of the organisers of both the Torino Steroid meeting (Gian 
Carlo Panzica) and of the former ICHBB (Jacques Balthazart). At a more scientific 
level, this 7th ICHBB also coincided with the 50th anniversary of the publication of the 
seminal paper of Phoenix and collaborators (10) universally recognised as the 
founding paper for the research analyzing the endocrine controls of sexual 
differentiation of brain and behaviour. 
With the exception of this satellite symposium, many of the talks and symposia 
mentioned above were not exclusively dedicated to the analysis of behaviour. They 
also concerned other topics such as the non-classical effects of steroids or the effects 
of steroids on the sexual differentiation of the brain. But in each case, they were 
behaviourally relevant in that either the changes in brain structure or function could 
contribute to explain behaviour or changes in behaviour were the driving force 
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leading to changes in the brain or in steroid synthesis. 
 
Ten years of progress in understanding sexual differentiation of the brain. 
What we knew at the beginning of the 21st Century. 
It has been a busy ten years for the field of behavioural neuroendocrinology and the 
topic of sexual differentiation of the brain in particular.  As we entered this century 
we had a strong foundation of immutable facts about the physiological process of 
sexual differentiation of brain and behaviour; 1) hormones of gonadal origin are the 
preeminent determinant of sex differences in brain and behaviour, 2) sex differences 
in levels of gonadal hormones during a sensitive period of brain development will 
organise the brain into a sex-specific phenotype and 3) sex differences in levels of 
gonadal hormones in adulthood will activate the previously determined sex-specific 
brain phenotype in order to drive sex-specific physiology and behaviour.  These are 
the basic facts but many aspects of the details vary by species, by physiological or 
behavioural endpoint and by brain region. In many cases the basic facts do not even 
apply. Nonetheless, the sturdy framework of the Organizational/Activational 
Hypothesis (10), which essentially codifies the three basic facts just enumerated, 
continues to provide a valuable backdrop against which to address all questions of the 
origins and significance of sex differences in the brain. Nothing is more valuable to 
scientific investigation than a dogma to be over thrown.  
Dogma’s overthrown. 
There have been several major challenges to the dogma in the past 10 years, some 
have indeed created a paradigm shift in our thinking while others have offered 
refinements and qualifiers, notable exceptions or a more nuanced understanding.  The 
biggest impact was the development of a mouse model that allowed for distinguishing 
between genetic, or chromosomal sex, and gonadal sex.  The generation of animals 
with an XX genotype and a male phenotype (i.e. testes) or an XY genotype and a 
female phenotype (i.e. ovaries), allowed Art Arnold and his collaborators to ask for 
the first time whether all sex differences in the brain are determined by hormones (3, 
11). The answer is, not surprisingly, mixed. Based on the current data to-date, it 
would appear that the sexual differentiation of endpoints that are directly relevant to 
reproduction, i.e. sexual behaviour and control of gonadotropin secretion and the 
brain areas that mediate them, are indeed subject to the classic hormonally mediated 
sexual differentiation of the brain. However, sex differences in endpoints that involve 
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cognition, emotion or sensory integration are often influenced by chromosomal sex, 
sometimes markedly so. The next ten years will no doubt further advance our 
knowledge on this front by using genetic models such as the steroidogenic factor 1 
(Nr5a1) knock-out mice which lack gonads (12) and by identifying specific X or Y 
genes and the associated mechanism of action. 
Discoveries more in the realm of refinements to the theory are found in the 
characterization of genetically modified mice in which aromatase, androgen receptor 
or either isoform of the oestrogen receptor (ER) is either globally or locally and 
conditionally ablated.  We have learned that in the rodent the long held dominance of 
oestradiol as the masculinizing hormone needs to make some room for androgens as 
important contributors to the natural process (13-18), and that ERα versus ERβ 
expression in a particular brain region mediates different responses (19-21). Our 
views of oestrogens effects have been further refined as well. First, steroid receptors 
are no longer mere transcription factors that mediate gene expression in a slow stately 
and direct manner, but instead can act rapidly at the membrane and integrate signal 
transduction pathways across a wide range of avenues (22, 23). Second, we now 
know oestradiol is more than just a gonadal hormone, it is also synthesised locally and 
rapidly and on demand, so much so that its resemblance to a neurotransmitters has 
been noted (24). Rapid membrane-mediated effects of oestradiol have been confirmed 
to contribute to the process of sexual differentiation of brain and behaviour (25), but 
what role local steroidogenesis plays in the process is not yet clear.  
Advances made. 
The distinction between the active processes of masculinisation and defeminisation of 
the male brain has long puzzled behavioural neuroendocrinologists and the last 
decade has seen several advances along this front. Characterization of null mutant 
mice suggests that the beta isoform of the oestrogen receptor is central to 
defeminisation (26), but how this is so is not clear. During the 2011 meeting a 
symposium was dedicated to the role of ERβ in adult brain function (27). The 
surprising discovery that the final common pathway mediating masculinisation of sex 
behaviour in the rat is the prostaglandin PGE2, also included the observation that 
prostaglandin mediated masculinisation does not influence defeminisation, and 
provided a unique tool for parsing out these separate processes in the same animal 
(28, 29).  Lastly, feminisation of brain development has always been the poor cousin 
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to the more tractable process of masculinisation but recent findings (30, 31) has 
revealed a heretofore unappreciated second sensitive period in which elevated 
oestradiol feminises the brain. This period is about a week to 10 days later than 
masculinisation in the rodent and elucidating the origins, sites of action and 
mechanisms of action of oestradiol during this later period will be an important topic 
in the coming years. 
Future directions 
At this writing we are at the beginning stages of several important new developments 
in the study of sex differences in the brain, some mechanistic and others theoretical.  
On the mechanistic front, it is apparent that the enduring organizational effects of 
steroids on the brain likely involve some sort of epigenetic changes to the genome.  
These include changes to the chromatin (32, 33) and the DNA (34-36), but how these 
changes are integrated, maintained or perhaps modulated, remains to be determined. 
Epigenetic changes are certainly regionally specific, and may be an important 
component of the regional specificity of hormone action in general.  This regional 
specificity compels us to reconsider the Organisational/Activational Hypothesis as 
many early hormonally mediated effects on the brain do not seem to follow the rules 
of this simple theory, suggesting new rules or guidelines are waiting for us to 
elucidate them. An important first step in that process comes from the novel view that 
we should also consider that the purpose of some sex differences in the brain is to 
make males and females more alike than different (37).  
 
Brain and behaviour, targets for the endocrine disrupters. 
The concept that exogenous substances may interfere with the normal development of 
brain and behaviour is not new, and it is at the basis of a large number of 
experimental studies. For instance, many studies on the sexual differentiation of 
rodent preoptic-hypothalamic circuits were conducted by using more powerful 
synthetic oestrogens like diethylstilbestrol [DES, (38)] or ethynylestradiol [EE2, (39)]. 
However, during the years it appeared that these substances and many others that are 
able to bind oestrogen or androgen receptors are not limited to the laboratory use, but, 
due to their large-scale use in pharmaceutical or other industries, they are also widely 
present in the environment. In addition, some molecules of natural origin, like 
phytoestrogens produced by a large number of plants and normally present in the 
animal and human food, may also interact with gonadal hormone receptors. 
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These substances were collectively named endocrine disrupters or endocrine 
disrupting chemicals (EDCs), a term that was coined early in 90’. In early papers (40), 
EDCs were defined as molecules that may disrupt the development of the endocrine 
system. In addition, the effects of EDCs’ exposure during development are often 
permanent. A large consensus on this idea came from the Endocrine Society that 
released a scientific statement outlining mechanisms and effects of EDCs (41). Even 
if neuroendocrinology was specifically mentioned, for many years the study of EDCs 
involved almost exclusively the toxicological aspects, whereas the neuroendocrine 
and behavioural implications of precocious exposure to EDCs were less investigated. 
Just from the first Torino’s meeting in 2001 the issue of neuroendocrine and 
behavioural effects of EDCs emerged as one of the main topics of the conference. In 
fact, in that occasion were presented data on the effects of phytoestrogens contained 
in the food on the expression and regulation of cerebral androgen and progesterone 
metabolizing enzymes (42), as well as on anxiety behaviour and visual-spatial 
memory (43, 44).  
During the 2nd meeting in 2003, a satellite symposium was dedicated to the 
action of environmental oestrogens on behaviourally relevant neural circuits. This 
symposium was the follow up of a series of meetings centered on the actions of EDCs 
on behaviour and associated neural circuits, considered as more sensitive endpoints 
than other targets (45, 46). 
The proceedings of this symposium (1) covered different experimental models 
including teleost fishes [somatostatin receptor (47)], birds [the vasotocin system (48, 
49), the catecholaminergic system (50), and the male copulatory behaviour (48, 51) of 
the Japanese quail], and rodents [catecholaminergic system (52), socio-sexual 
behaviours (53-55), oestrogen receptors (56), and brain plasticity (57, 58)]. These 
contributions provided important information on the action of single EDCs, as well as 
insights into the neural mechanisms by which these EDCs exert their effects. 
During the 3rd meeting, data on the rapid influence of oestrogens on the 
excitability of adult rat hippocampal neurones were presented (59-61). These findings 
have led researchers to postulate the existence of so-called membrane or non-genomic 
oestrogen effects. EDCs able to bind oestrogen receptors (xenoestrogens) also act 
rapidly in the adult brain. For example, the oestradiol-induced enhancement of the 
long-term potentiation in CA1 upon tetanic stimulation was considerably suppressed 
by the co-perfusion with bisphenol A (BPA), although the perfusion of BPA alone did 
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not alter the LTP-induction (62). On the other hand, DES enhanced the LTP by an 
almost identical magnitude to that obtained by oestradiol. EDCs can reach the brain 
via the blood circulation and by crossing the blood–brain barriers.  
A symposium on the cerebral effects of xenoestrogens was again organised 
during the 4th meeting. This symposium included studies on the effects of BPA on the 
modulation of long-term depression and spinogenesis in the hippocampus (63), on the 
expression of oestrogen receptor (64), and on the development of the rodent (65) and 
avian brain (66). 
During the 5th meeting, endocrine disruptors were considered among the wide 
family of steroid receptors coactivators (67), in particular modulating the expression 
of sexually dimorphic social and emotional behaviours (68). Finally, during the last 
meeting, whose proceedings are collected in this special issue, a round table on 
endocrine disrupter action on behaviour and neuroendocrine system has been 
organised (69). 
In summary, during these ten years we observed an increasing interest in the 
field of EDCs, mainly related to the potentially adverse effects on the sexual 
differentiation of brain and behaviour. Some important facts emerged in this field:  
- sexual behaviour and neural circuits related to its control are more sensitive 
endpoints than others currently used in toxicological studies (70, 71); 
- neuropeptides and enzymes are major targ ts for the action of EDCs in the 
vertebrate brain (72); 
- among different peptidergic systems kisspeptin in rodents (73-77), vasotocin in 
birds (48, 78, 79), as well as the enzyme aromatase in fishes (80-82), or the 
enzyme NO-synthase in rodents (83, 84) appear the most sensitive to low levels of 
EDCs during early development; 
- alterations of these circuits may induce profound effects on sexual behaviour (85), 
puberty (74), reproductive physiology (86), and feeding behaviour (87); 
- neural circuits can be altered also at synaptic levels, for example in the 
hippocampus (63, 88-90) and have profound effects on learning and memory (91); 
- the putative mechanisms of action needs to be more thoroughly explored (69), but 
in addition to the EDCs binding to steroid or thyroid hormone receptors, they 
include the aryl hydrocarbon receptor, its interactions with ERβ, the activation of 
the P450 cytochromes, which are involved in the metabolism of most steroid 
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hormones, the PPARγ and retinoid receptors particularly important in adipose 
tissue. 
 
Synthesis of neurosteroids 
In the research area on steroids and nervous system, the 3 last decades were 
significantly marked by a major finding that revealed that neurones and glial cells 
have the ability to synthesise bioactive steroids, also called neurosteroids (92). This 
important discovery stemmed from a series of pioneer works showing the persistence 
of substantial amounts of pregnenolone, dehydroepiandrosterone and their sulfated 
derivatives in the rodent brain after adrenalectomy and/or gonadectomy (93, 94). 
However, the consolidation of the concept of neurosteroids required several 
investigations performed in different animal species (92, 95-97).  
Since its creation, the International Meeting Steroids and Nervous System has steadily 
contributed through various symposia and plenary lectures to the elucidation of the 
biosynthetic pathways and mechanisms of action of neurosteroids. For instance, the 
first meeting (2001) has been launched with a symposium that provided key data on 
neurosteroid biosynthesis in mammalian and non-mammalian vertebrates (98, 99). 
The second meeting allowed fruitful discussion from talks on neurosteroid 
metabolism in the human brain (100) or neurosteroid production in the retina (101). 
During the 3rd meeting (2005), a satellite symposium made it possible to discuss the 
neuroprotective effects of steroids locally produced by the spinal cord and peripheral 
nervous system (102). In addition, a symposium of the main meeting discussed the 
role of steroidogenic acute regulatory protein and peripheral benzodiazepine receptors 
in neurosteroid biosynthesis (103, 104). Novel technological tools allowing high-
sensitive dosage of neurosteroids were presented in a satellite symposium of the 4th 
meeting (105). To review and update the current knowledge on neurosteroid synthesis 
and functions, the opening lecture of the 6th meeting was dedicated to a comparative 
and functional analysis of neurosteroidogenesis (8), and a satellite symposium was 
focused to neuroactive steroids in the human brain (106).  
Taken together, all of the data provided by renowned experts in symposia and 
proceedings of the International Meeting Steroids and Nervous have significantly 
contributed to clarify the biosynthetic pathways and physiopathological relevance of 
neurosteroids. Nowadays, a consensual definition of neurosteroids considers these 
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molecules as endogenous steroidal compounds synthesised in neurones or glial cells 
of the CNS and PNS. To be qualified as a neurosteroid, the candidate steroidal 
molecule must persist in substantial amounts in the nervous system after removal of 
the peripheral or traditional steroidogenic glands such as the adrenals and gonads. The 
demonstration of neurosteroid biosynthesis requires the localization in nerve cells of 
the translocator protein 18 kDa, the steroidogenic acute regulatory protein and active 
steroidogenic key enzymes such as cytochrome P450 side chain cleavage, 3β-
hydroxysteroid dehydrogenase, cytochrome P450c17, 5α-reductase, 3α-
hydroxysteroid oxido-reductase, 17β-hydroxysteroid dehydrogenase and aromatase 
(92, 95-97, 107, 108).  
Finally, it should also be noticed that endogenous neurosteroids act as paracrine or 
autocrine factors, regulating the activity of classical nuclear steroid receptors or 
membrane receptors including G protein-coupled receptors (109, 110), GABAA and 
T-type calcium channels (111-114) or NMDA (115, 116), P2X (117) and sigma 
receptors (118, 119). 
 
Neuroendocrine control of reproduction by steroids 
Another area of research that has featured strongly at the Torino meetings over the 
last ten years has been that of how gonadal steroids modulate the gonadotropin-
releasing hormone (GnRH) neurones that control fertility.  Since 2001 much has 
changed in this field and this has been reflected in the Torino presentations. Firstly, 
the techniques used by GnRH neurone investigators have changed considerably. This 
has been driven primarily by the use of genetic manipulations in mice that have 
greatly facilitated investigation of the GnRH neurone and its network. As reflected in 
the 2001 meeting, the mainstay approaches of the field at that time were in situ 
hybridization for GnRH mRNA, one of the few direct indices of GnRH neurones at 
the turn of the century (120), and use of the immortalised embryonic GT1 cell lines 
that synthesise GnRH (121). By 2011, a range of sophisticated transgenic and cell- or 
receptor-specific gene mutation approaches were being used to establish the electrical 
properties, gene expression profiles and in vivo significance of GnRH neurone-
selective receptor manipulations. The second major change in this field has been the 
discovery of kisspeptin.  Initially discovered in humans in 2003 (122, 123), GnRH 
neurone investigators rapidly took up the challenge of deciphering how kisspeptin 
regulates fertility and this topic has been present at meetings since 2007 (124-126).  
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The key gonadal steroid-GnRH neurone milestones at Torino meetings over the last 
10 years have been summarised in the following sub-chapters. 
Understanding rapid gonadal steroid actions on GnRH neurones.  
The meeting has witnessed the gradual unfolding of how oestrogens, androgens and 
progesterone derivatives exert rapid, sometimes direct, actions upon GnRH neurones. 
At the 2001 meeting, the role of allopregnanolone on GABAA-mediated effects on 
GnRH neurones in GT1 cells (127) and native adult GnRH neurones (128) was 
discussed. This was followed at the next meeting in 2003 by descriptions of how 
oestradiol rapidly activates specific intracellular signaling cascades in GnRH 
neurones, including calcium dynamics. These actions were mediated directly by ERβ 
expressed by GnRH neurones as well as indirectly through GABAA receptors (129, 
130).  This line of work was brought up to date at the most recent meeting in 2011 
where studies detailing the complex, dose-dependent direct- and indirect- effects of 
oestradiol (131, 132) and androgen metabolites (133, 134), on GnRH neurone 
electrical activity were presented. Although the issue of the physiological relevance of 
rapid steroid actions remains unknown (135), it is clear that progesterone and 
androgen derivatives, as well as oestradiol itself, can exert rapid actions on 
mammalian GnRH neurones both directly, and indirectly through GABA and 
glutamatergic inputs to these cells.   
 Examining the role of glial cells and growth factors in the steroid regulation of 
GnRH neurones.  
The importance of astrocytic growth factors such as TGFβ and βFGF on the 
functioning of GT1 cells (121) was elucidated during the 2001 meeting. This was 
expanded in 2003 to document the role that oestradiol played in regulating glial 
production of these growth factors (136). At the same meeting, the key roles for IGF-
1 interactions with oestradiol in modulating adrenergic tone within the GnRH 
neuronal network in vivo were illustrated (137). This was to be expanded further in 
2007 meeting by showing that oestradiol acts on membrane ERs on glial cells to 
promote progesterone synthesis that, in turn, impacts on the ability of GnRH neurones 
to exhibit the preovulatory surge (138). Alongside many other talks at the Torino 
meeting on steroid hormone-growth factor interactions, these studies have provided 
the impetus for considering the potentially important impact of glial cells on GnRH 
neurone functioning.  The lack of good tools to dissect the roles of specific groups or 
Page 12 of 43Journal of Neuroendocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Ten years of the Torino Steroids’ Meeting 
 13
regional locations of glia in vivo seems to remain a significant problem for 
understanding the roles of these cells beyond their normal “neuronal support roles”. 
Defining the mechanisms of oestrogen positive and negative feedback.   
Talks presented in 2001 meeting focused upon the roles of gonadal steroids in 
regulating GnRH gene transcription using in situ hybrization (120) and GnRH 
transgenics (139), respectively. This topic moved a considerable step forward with the 
data presented at the 2003 meeting detailing the effects of ovariectomy and oestrogen 
replacement upon GnRH neurone firing rates and the potential ion channels 
underlying these actions (140).  It would not, however, be until the 2011 meeting that 
the data on single cell RT-PCR allowed to define the precise ion channel subunits 
modulated by oestradiol in GnRH neurones (141, 142). The GnRH neurone firing 
studies in 2003 were complemented by studies showing the effects of different steroid 
regimens upon pulsatile GnRH secretion from hypothalamic explants (143).  
Although from different species, this highlighted the continuing puzzle as to why the 
effects of ovariectomy and oestradiol replacement on GnRH neurone firing rates and 
GnRH secretion are so dissimilar. The 2007 meeting was presented with a series of 
genetic and ER-specific ligand studies (144, 145) that defined the mechanism and 
types of ERs involved in the positive feedback mechanisms in mice and rats. These 
studies concluded that oestradiol acted on ERα-expressing neurones in the rostral 
hypothalamus to activate GnRH neurones to evoke the GnRH surge (124). Other 
studies presented at that meeting highlighted the oestrogen-sensitivity of kisspeptin 
neurones (125).  By the time of the 2011 meeting the promise of the oestradiol-
sensitive kisspeptin neurones within the GnRH neuronal network had been fulfilled 
with three papers (126, 146, 147) detailing their now established key importance in 
different oestrogen feedback mechanisms.  
Over the last 10 years, the Torino meeting has provided one focus meeting for 
promoting the understanding of how gonadal steroids modulate the behaviour of 
GnRH neurones.  This is a large subject with too many active investigators to 
accommodate at the Torino meeting at one time. Nevertheless, those outside the field 
have been treated to a consistently high-quality overview of progress in the subject 
while GnRH neurones aficionados have had the luxury of discussing science in the 
delightful mid-winter setting of Torino. 
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Interactions with classical and non classical steroid receptors 
Through the years at the International Conference on Steroids and the Nervous 
System, there has been much work presented on the mechanisms by which steroids 
may exert some of their effects. Nuclear steroid receptors (nSRs) were discovered 
over 50 years ago for oestrogen and were followed by discovery of specific nSRs for 
progestins and androgens (148). These classic nSRs are intracellular, are activated by 
the binding of steroids, and serve as transcription factors. Our discussions of 
oestrogen action in the brain via nSRs has included actions via the originally 
discovered ERα and its traditional role in reproduction, but also how these actions 
have effects in other brain regions such as the hippocampus, to influence processes 
relevant for aging and related functions (149). Various effects, from form to function, 
of the more recently discovered ERβ have been discussed (27, 150), with an emphasis 
on integrated actions via ERα and ERβ (5).  The role of progestin receptors in 
reproduction, and their effects as neural integrators of hormonal and environment 
actions, have been proposed (151, 152). How actions at progestin receptors may occur 
through steroid activation or involve other ligands, such as dopamine, is intriguing 
(153). At this venue, we have also discussed the role of androgens receptors in sexual 
differentiation, and other processes, along with how there may be actions of 
androgens via other nSRs, including ERbeta, as well as actions apart from nSRs (15, 
16, 154-158). 
More recently, it has been demonstrated that steroids bound to nSR complexes, 
bind hormone response elements, and have actions through co-activators, to result in 
changes in their rates of transcription and translation. The importance of co-regulatory 
factors to influence nSRs action has been discussed at our venue (159).  How steroids’ 
actions in the brain via sNRs can also involve coactivators, which modulate hormone-
dependent gene expression in brain and reproductive behaviour in rodents (67) and 
galliforms (159), and co-repressors, such as chromatin binding factors mediation of 
epigenetic organization of sex differences in the brain (160), has been the topic of 
recent symposia.  Thus, as evidence has emerged regarding steroids actions via nSRs, 
these topics have been of ongoing interest and discussion. 
This classical “genomic” mechanism of steroid action, involving the 
transcription of DNA and synthesis of proteins, can elicit a biological response within 
10 minutes, hours or days. In addition to classical actions via nSRs, there has been an 
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ongoing dialogue about non-traditional actions of steroids.  Non-classical actions of 
steroids can occur much more rapidly (<10 minutes, and even in seconds) than actions 
at nSRs, in the absence of nSRs, and in the presence of inhibitors of transcription 
and/or translation. Non-classical, rapid steroid actions, often referred to as “non-
genomic” actions of steroids, have been extensively studied over the past few 
decades, demonstrated for all the major classes of steroids, and are now well-
recognised.  Rapid, non-classical actions of oestrogens, progestogens, and androgens 
and their role in various hormone-sensitive functions, have been ongoing topics of 
discourse at this meeting (4, 69, 89, 161, 162). 
An important question is which receptors mediate non-genomic actions? 
Several physiologically relevant membrane-associated proteins have been identified 
on plasma membranes suggesting the existence of specific membrane steroids 
receptors (22, 23, 163-165). However, identities of some of these membrane targets 
remain controversial.  Neurotransmitter receptors have been foci of non-genomic 
signaling activity of steroids. The most widely studied (and discussed) 
neurotransmitter targets for steroid actions have been through GABA receptors (166-
173). However, actions of steroids through glutamate (120, 174), dopamine (175), 
adrenergic (137, 176, 177), opiate (178), and sigma (179) receptors have been 
investigated and discussed at this meeting. 
Some non-traditional effects of steroids may be downstream of actions at 
membrane targets. The intracellular signal transduction cascades, which mediate some 
behavioural effects of ovarian steroids have been discussed (137, 176).  Some effects 
of steroids, such as progestagens, may be mediated in part through adenyl cyclase, G-
proteins, PKA, PLC, and/or PKC pathways (180, 181).  Other effects of oestrogen 
may be mediated through MAPK signaling, mitochondrial processes, or other 
intracellular pathways. (182). Extensive discussions of traditional and novel effects 
and mechanisms of steroids have taken place during the meetings organised in Torino.  
There have also been perspectives of how actions through classic nSR signaling may 
integrate with rapid, membrane action of steroids, and their downstream effectors 
(183, 184).  The discourse to date about classic and non-traditional steroid action have 
been productive and will likely continue to expand the field in a substantive manner 
to elucidate new perspective regarding modulatory effects of steroid signalling. 
 
Neuroactive steroids as neuroprotective agents: translational research 
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The role of neuroactive steroids on neurodegeneration, neuroprotection and the 
response of the neural tissue to injury has been a fundamental topic in the 
International Meeting on Steroids and Nervous System since its first edition in 2001. 
Since then, this field has significantly advanced and neuroactive steroids have 
emerged as new potential therapeutic tools to counteract neurodegenerative events. 
Oestradiol and neuroprotection 
By the time of the first Torino meeting extensive experimental evidence indicated that 
oestradiol is neuroprotective (126). However, a turning point was the publication of 
the results of the Women’s Health Initiative (WHI) clinical trial on the effects of 
hormonal therapy in women (185, 186). The results of this study showed an increased 
risk of dementia and stroke in women over 65 years of age who received conjugated 
equine oestrogens plus medroxyprogesterone acetate (MPA) compared to women who 
received placebo. This finding was in contradiction with the evidence obtained in 
animal models of neurodegenerative diseases. Therefore, new studies have addressed 
in recent years the possible causes of this discrepancy. In particular, age at which 
hormones were administered relative to the perimenopausal transition has emerged as 
a critical issue. Observational studies and randomised clinical studies suggest that 
early initiation of hormone therapy may provide cognitive benefits, particularly to 
verbal memory and other hippocampus-mediated functions (187). In addition, new 
basic studies have shown that the neuroprotective activity of oestradiol depends on 
the duration of ovarian hormone deprivation (188) and is affected by age-associated 
modifications in the levels of other molecules, such as insulin-like growth factor-I 
(189).  
Progesterone and other neurosteroids 
Another neuroactive steroid whose neuroprotective activity has been frequently 
discussed in Torino meetings is progesterone. The neuroprotective activity of 
progesterone and its metabolites dihydroprogesterone and tetrahydroprogesterone has 
been characterised in the last decade (190-192). Progesterone and its metabolites 
promote remyelination in the CNS (193, 194) and the PNS (195-197). Furthermore, 
progesterone attenuates clinical severity, demyelination, neuronal dysfunction and 
axonal damage in experimental autoimmune encephalomyelitis, a well-established 
experimental model of multiple sclerosis (198-201) and in diabetic neuropathy (202). 
Progesterone is also protective after traumatic brain injury in animals (192). In 
addition, clinical trials have indicated a reduction in the mortality and an 
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improvement of functional outcomes after traumatic brain injury in patients treated 
with progesterone (203). 
The neuroprotective action of other neuroactive steroids has also been assessed during 
the last decade. Among these is allopregnanolone, whose cerebral levels are decreased 
in an experimental model of Niemann-Pick type C disease. The neonatal 
administration of allopregnanolone results in a delay of the onset of neurological 
symptoms, and a doubling the lifespan of the animals (204). Other studies have 
demonstrated the efficacy of treatment with dehydroepiandrosterone after spinal cord 
injury (205) and in diabetic neuropathy (206). Neuroactive steroids are also important 
endogenous modulators of mood and have therapeutic potential for the treatment of 
depression and anxiety disorders. Novel therapeutic strategies might either be based 
on synthetic derivates of endogenous 3alpha-reduced neuroactive steroids or on the 
modulation of neurosteroidogenic activity (207). Pregnenolone and 
dehydroepiandrosterone are also promising candidates for the treatment of 
schizophrenia (208, 209). Better performance on executive tasks is associated with 
increased plasma levels of dehydroepiandrosterone in schizophrenic patients (209) 
and clinical trials have demonstrated that pregnenolone is able to decrease negative 
symptoms and extrapyramidal side effects and to improve verbal memory, attention 
and working memory performance in these patients (208).  
Alternatives to treatment with neuroactive steroids have been also explored in recent 
years. These include synthetic receptor modulators, like for instance selective 
oestrogen modulators (SERMs). Some SERMs have been shown to be 
neuroprotective and anti-inflammatory agents in experimental animal models of 
central neurodegeneration (210). Another alternative therapeutic strategy might be the 
use of pharmacological agents that increase the synthesis of endogenous neuroactive 
steroids within the nervous system (211). With this perspective, ligands of 
translocator protein (TSPO, previously known as peripheral benzodiazepine receptor 
(104)) may represent an interesting option (212-214). TSPO is mainly present in the 
mitochondrial outer membrane, where it promotes, in cooperation with steroidogenic 
acute regulatory protein (StAR), the translocation of cholesterol to the inner 
mitochondrial membrane. The mitochondrial translocation of cholesterol is a limiting 
step in steroidogenesis, since it allows the transformation of cholesterol into 
pregnenolone. Observations have shown that treatment with ligands of TSPO, like for 
instance Ro5-4864, exerts neuroprotective effects in aged peripheral nervous system 
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(215), in peripheral nerve during diabetes (216) and in CNS after neuronal injury 
(217). A similar approach has been obtained with a ligand of liver X receptors. 
Indeed, treatment of diabetic animals with a synthetic ligand of these receptors (i.e., 
GW3965) results in an increase of neuroactive steroidoigenesis in the sciatic nerve 
which is associated with neuroprotective effects (218).  
Perspectives for the future 
During the last decade several studies have shown that pathological events have an 
important impact on neuroactive steroid levels in nervous tissues. Changes in 
neurosteroid biosynthesis or in neurosteroid levels in the brain, spinal cord or 
peripheral nerves have been detected under different pathological conditions, 
including experimental models of diabetes (219-221), hereditary peripheral 
neuropathy (219), peripheral nerve injury (222), spinal cord injury (223, 224), 
multiple sclerosis (225, 226), autism (227), and Parkinson's disease (228, 229). 
Neuroactive steroid levels are also modified in the human brain under pathological 
conditions, including Alzheimer’s disease, Parkinson's disease, multiple sclerosis and 
hepatic encephalopathy (97, 230-235). To develop adequate therapeutic tools based 
on neuroactive steroids (212-214) it would be necessary to increase our knowledge on 
the specific regional and temporal changes that occur in neurosteroid levels in the 
human brain at different phases of neurodegenerative diseases and during affective 
disorders. In addition, it would be also necessary to determine the implications of 
such changes for the manifestation and outcome of the pathological condition.   
Another important issue is that different pathologies of the central and 
peripheral nervous system show sex differences in their incidence, symptomatology 
and/or neurodegenerative outcome (236). Interestingly, the levels of neuroactive 
steroids in the CNS and PNS under pathological conditions also show sex differences 
(219, 221, 224-226, 237, 238). In addition, the nervous system of males and females 
show different responses to neuroactive steroids. Therefore, it would be important to 
explore with detail the interaction of sex with neurosteroid levels and neurosteroid 
actions to develop adequate sex-specific neuroprotective strategies. 
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Legend to the figure 
 
Fig. 1 – Participants at the 6th International Meeting on Steroids and Nervous System, 
Torino, February 2011. 
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Fig. 1 – Participants at the 6th International Meeting on Steroids and Nervous System, Torino, February 
2011.  
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